Top-Down Fabricated microPlates for Prolonged, Intra-articular Matrix Metalloproteinase 13 siRNA Nanocarrier Delivery to Reduce Post-traumatic Osteoarthritis

Authors:

Abstract
Post-traumatic osteoarthritis (PTOA) associated with joint injury triggers a degenerative cycle of matrix destruction and inflammatory signaling, leading to pain and loss of function. Here, prolonged RNA interference (RNAi) of matrix metalloproteinase 13 (MMP13) is tested as a PTOA disease modifying therapy. MMP13 is upregulated in PTOA and degrades the key cartilage structural protein type II collagen. Short interfering RNA (siRNA) loaded nanoparticles (siNPs) were encapsulated in shape-defined poly(lactic-co-glycolic acid) (PLGA) based microPlates (μPLs) to formulate siNP-μPLs that maintained siNPs in the joint significantly longer than delivery of free siNPs. Treatment with siNP-μPLs against MMP13 (siMMP13-μPLs) in a mechanical load-induced mouse model of PTOA maintained potent (65–75%) MMP13 gene expression knockdown and reduced MMP13 protein production in joint tissues throughout a 28-day study. MMP13 silencing reduced PTOA articular cartilage degradation/fibrillation, meniscal deterioration, synovial hyperplasia, osteophytes, and pro-inflammatory gene expression, supporting the therapeutic potential of long-lasting siMMP13-μPL therapy for PTOA.
Funding Information
  • U.S. Department of Health and Human Services (2P30 CA068485-14)
  • Rheumatology Research Foundation
  • U.S. Department of War (OR130302)
  • European Commission (616695)
  • U.S. Department of Health and Human Services (R01 CA224241, R01 EB019409, S10RR027631-01, T32GM007347)
  • National Science Foundation (2016212929)
  • VA Merit Award (BX004151)
  • National Science and Engineering Research Council (NSERC)
  • European Union????s Horizon 2020 Research and Innovation Programme under the Marie Sklodowska- Curie (754490, 872648)

This publication has 79 references indexed in Scilit: